Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials

Vistagen Therapeutics, Inc.

FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.
Cash, cash equivalents and marketable securities $80.5M as of March 31, 2025.
PALISADE-3 fasedienol topline results expected Q4 2025; PALISADE-4 results expected H1 2026.
Filed prospectus supplement to sell up to $175M common stock via ATM (replacing $100M prior); ~$3.4M already sold.
Itruvone for MDD planning further Phase 2; PH80 for menopausal hot flashes preparing U.S. IND.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.